Redmile Group Lowered Clovis Oncology (CLVS) Position, Relm Wireless (RWC)’s Sentiment Is 0.56

June 20, 2017 - By marketbeat

RELM Wireless Corporation provides two-way radio communications equipment. The company has market cap of $53.96 million. RELM designs, makes and markets wireless communications products consisting of two-way land mobile radios, repeaters, base stations, and related components and subsystems. It has a 56.89 P/E ratio. Two-way land mobile radios include units that are hand-held (portable) or installed in vehicles (mobile).

Redmile Group Llc decreased Clovis Oncology Inc (CLVS) stake by 20.96% reported in 2016Q4 SEC filing. Redmile Group Llc sold 429,630 shares as Clovis Oncology Inc (CLVS)’s stock declined 20.61%. The Redmile Group Llc holds 1.62 million shares with $71.98M value, down from 2.05M last quarter. Clovis Oncology Inc now has $5.95 billion valuation. The stock rose 3.22% or $2.83 reaching $90.71. About 4.44M shares traded or 127.69% up from the average. Clovis Oncology Inc (NASDAQ:CLVS) has risen 282.71% since June 20, 2016 and is uptrending. It has outperformed by 266.01% the S&P500.

Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on August, 14. They expect $-1.37 EPS, up 33.82% or $0.70 from last year’s $-2.07 per share. After $-1.33 actual EPS reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts 3.01% negative EPS growth.

Among 14 analysts covering Clovis Oncology (NASDAQ:CLVS), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Clovis Oncology had 36 analyst reports since September 10, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Clovis Oncology Inc (NASDAQ:CLVS) on Monday, January 23 with “Buy” rating. The firm has “Sell” rating given on Friday, February 3 by Chardan Capital Markets. The stock has “Buy” rating by SunTrust on Friday, September 23. The firm has “Buy” rating by Suntrust Robinson given on Wednesday, August 24. The stock has “Buy” rating by WallachBeth Capital on Thursday, September 10. The firm has “Neutral” rating given on Monday, November 16 by Mizuho. The rating was maintained by Piper Jaffray on Monday, November 16 with “Neutral”. The firm has “Buy” rating by Suntrust Robinson given on Friday, September 23. The company was reinitiated on Monday, April 4 by Piper Jaffray. The rating was upgraded by Chardan Capital Markets on Monday, June 19 to “Neutral”.

Investors sentiment decreased to 1.03 in Q4 2016. Its down 0.97, from 2 in 2016Q3. It turned negative, as 30 investors sold CLVS shares while 48 reduced holdings. 38 funds opened positions while 42 raised stakes. 35.69 million shares or 2.51% less from 36.61 million shares in 2016Q3 were reported. Partner Fund LP reported 1.28 million shares stake. Deutsche Commercial Bank Ag reported 126,195 shares or 0% of all its holdings. Guggenheim Capital Ltd Liability reported 63,568 shares. 5,067 were reported by Quantitative Systematic Strategies Ltd Liability Corp. Palo Alto Ltd Llc invested in 9.64% or 3.80 million shares. D E Shaw & invested 0.05% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Atwood Palmer accumulated 0% or 100 shares. Perceptive Advsrs Limited Co reported 167,754 shares. Redmile Grp Limited Liability Corporation holds 6.2% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 1.62M shares. Invesco holds 0% or 114,298 shares in its portfolio. Blackrock Ltd Llc reported 60,785 shares stake. Meeder Asset Mgmt has 214 shares for 0% of their portfolio. Apriem Advisors reported 400 shares. Marshall Wace Limited Liability Partnership accumulated 83,014 shares or 0.02% of the stock. Geode Cap Management Limited Company, Massachusetts-based fund reported 290,450 shares.

Redmile Group Llc increased Chimerix Inc (NASDAQ:CMRX) stake by 131,013 shares to 3.35 million valued at $15.39 million in 2016Q4. It also upped Ariad Pharmaceuticals Inc (NASDAQ:ARIA) stake by 1.70 million shares and now owns 3.84M shares. Neuroderm Ltd was raised too.

Since March 15, 2017, it had 0 insider purchases, and 3 sales for $528,600 activity. IVERS-READ GILLIAN C also sold $200,970 worth of Clovis Oncology Inc (NASDAQ:CLVS) on Wednesday, March 15.

Since January 1, 0001, it had 2 insider purchases, and 1 insider sale for $1.50 million activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: